Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases

Grzegorz Bulaj1,*, Margaret M. Ahern2, Alexis Kuhn2, Zachary S. Judkins2, Randy C. Bowen3 and Yizhe Chen4,

1Department of Medicinal Chemistry, University of Utah, Salt Lake City, Utah 84112, USA; 2College of Pharmacy, University of Utah, Salt Lake City, Utah 84112, USA; 3School of Medicine, University of Utah, Salt Lake City, Utah 84112, USA; 4Department of Pharmaceutics, University of Utah, Salt Lake City, Utah 84112; USA; 1Current address: Department of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA

Abstract: Merging pharmaceutical and digital (mobile health, mHealth) ingredients to create new therapies for chronic diseases offers unique opportunities for natural products such as omega-3 polyunsaturated fatty acids (n-3 PUFA), curcumin, resveratrol, theanine, or α-lipoic acid. These compounds, when combined with pharmaceutical drugs, show improved efficacy and safety in preclinical and clinical studies of epilepsy, neuropathic pain, osteoarthritis, depression, schizophrenia, diabetes and cancer. Their additional clinical benefits include reducing levels of TNFα and other inflammatory cytokines. We describe how pleiotropic natural products can be developed as bioactive incentives within the network pharmacology together with pharmaceutical drugs and self-care interventions. Since approximately 50% of chronically-ill patients do not take pharmaceutical drugs as prescribed, psychobehavioral incentives may appeal to patients at risk for medication non-adherence. For epilepsy, the incentive-based network therapy comprises anticonvulsant drugs, antiseizure natural products (n-3 PUFA, curcumin or and resveratrol) coupled with disease-specific behavioral interventions delivered by mobile medical apps. The add-on combination of antiseizure natural products and mHealth supports patient empowerment and intrinsic motivation by having a choice in self-care behaviors. The incentivized therapies offer opportunities: (1) to improve clinical efficacy and safety of existing drugs, (2) to catalyze patient-centered, disease self-management and behavior-changing habits, also improving health-related quality-of-life after reaching remission, and (3) merging copyrighted mHealth software with natural products, thus establishing an intellectual property protection of medical treatments comprising the natural products existing in public domain and currently promoted as dietary supplements. Taken together, clinical research on synergies between existing drugs and pleiotropic natural products, and their integration with self-care, music and mHealth, expands precision/personalized medicine strategies for chronic diseases via pharmacological-behavioral combination therapies.

Keywords: Drug-resistant epilepsy, refractory epilepsy, inflammation, addiction, cognitive behavioral therapy, brain-derived neurotropic factor, music, Mozart, video games.

INTRODUCTION

In addition to search for more effective pharmacological treatments, therapies for chronic diseases have been challenged by medication non-adherence. Due to real-life factors, the complexity of health care delivery, and compromised patient behaviors, this global health care problem is also being addressed by self-care interventions [1]. Another challenge to improve therapies for chronic diseases is to convert clinically-beneficial natural products into medical treatments due to their public domain status [2]. These two challenges can be simultaneously tackled by overlapping opportunities in digital/mobile medical technologies which can deliver disease self-management content, new intellectual property and patient engagement [3]. This review describes new opportunities to address the aforementioned challenges by combining natural products with pharmaceutical drugs and behavioral interventions. For natural products which improve clinical outcomes, one
strategy to convert them into medical treatments is by combining them as psychobehavioral incentives together with pharmaceutical drugs and mobile medical software. In the first part, we review clinical and preclinical studies supporting combination therapies consisting of pleiotropic natural products and pharmaceutical drugs. In the second part, we describe medication non-adherence for chronic disorders and premise of using natural products as psychobehavioral incentives to improve therapy outcomes. In the third section, we review evidence for combining antiseizure drugs with natural products and behavioral interventions for the treatment of epilepsy, as an example of incentivized therapy for a chronic disease. Lastly, we provide translational and industry considerations of developing molecular-behavioral combination therapies for chronic medical conditions by merging pharmaceutical and digital ingredients via mHealth.

Pleiotropic Natural Products and their Combinations with Pharmaceutical Drugs

Pleiotropic natural products such as omega-3 polyunsaturated fatty acids (n-3 PUFA), α-lipoic acid, curcumin, L-theanine, or trans-resveratrol are extensively tested in clinical trials, while also commonly used as dietary supplements (Fig. 1A) [4-10]. These pleiotropic natural products produce multiple physiological responses through concurrent targeting of various receptors and signaling pathways, and/or scavenging free radicals. Reviews on mechanisms of action for these compounds have been published [11-15]. n-3 PUFA target peroxisome proliferator-activated receptors (PPARs) and NFκB transcription factors, selected G-protein coupled receptors, and can also affect cell membrane compositions and metabolic pathways for synthesis of pro-inflammatory eicosanoids [12, 13, 15-17]. α-Lipoic acid mediates antioxidant activity, chelation of metal ions, inhibition of NFκB and PPARs expression, and modulates lipid and glucose metabolism. Curcumin exerts antioxidant, anticancer and anti-inflammatory activities by targeting redox and inflammatory pathways via Nrf2, NFκB, COX-2, STAT and MAP kinases, as well as cyclin D1, MMP9, VEGF and CXCR4 [5, 11, 14, 18]. Resveratrol can activate α- and β- estrogen receptors, and also modulates diverse antioxidant, apoptotic and inflammatory pathways by activating or inhibiting PPARα, Nrf2, NFκB, SIRT1, AMPK, COX1/2 among others [8, 19-23]. These natural products modulate inflammatory cytokines, including TNFα, IL-1 and IL-6 [4, 24-27]. Neuropharmacological effects of theanine are mediated via several receptors (GABA(A), NMDA, AMPA, kainite), the nitric oxide pathway, and upregulated expression of brain-derived neurotrophic factor (BDNF) [28-32]. Taken together, pleiotropic natural products can be considered as “a single compound with selective polypharmacology” (Fig. 1B) [33-35].

Clinical studies of the pleiotropic natural products suggest their favorable tolerability, safety and efficacy in several medical indications. n-3 PUFA (omega-3-acid ethyl esters; Lovaza® by GlaxoSmithKline) was approved by the US Food and Drug Administration as an adjunct therapy for patients with severe hypertriglyceridemia [36]. Clinical data on metabolism and toxicity of resveratrol suggest that it is

Fig. (1). Structures of selected pleiotropic natural products (A), and their multiple functions within the network pharmacology (B). Pleiotropic natural products exert pharmacological properties via specific molecular targets and signaling pathways, while also delivering anti-inflammatory activities. Additional benefits of pleiotropic natural products may include antidepressant, cardiovascular, metabolic, neuroprotective, cognitive, antioxidant, or anticancer activities [11-15, 41].
well tolerated, but clinical efficacy data remain limited [9, 37, 38]. Repeated administration of formulatated curcumin (200 mg or 400 mg daily) in cancer patients was safe and well tolerated [39]. Six-week treatments with curcumin (1000 mg/day) appeared safe for patients with major depressive disorders [40]. Safety, tolerability and efficacy of α-lipoic acid was studied in diabetes, Alzheimer’s disease (AD), multiple sclerosis (MS), neuropathy and pain [27, 41-45]. Theanine has been clinically tested in patients with schizophrenia [46] and attention-deficit hyperactivity disorder (ADHD) [28]. The pleiotropic natural products are clinically tested as monotherapies or as adjunct therapies to existing medical treatments. Examples of clinical trials showing improved efficacy by combining selected natural products with analgesics, anti-seizure, anticancer, antidiabetic, or antidepressant drugs are shown in Table 1. New opportunities for n-3 PUFA also include cystic fibrosis [47] and asthma [48]. Despite positive effects of the natural products on specific medical conditions (n-3 PUFA in cardiovascular disease (CVD), α-LA for diabetic neuropathy, curcumin in depression), clinical trials of the natural products tested as monotherapies sometimes report inconclusive or negative results. There are also emerging reports which suggest prostate cancer or metabolic risks associated with n-3 PUFA supplementation [49, 50]. Taken together, current clinical results on the natural products suggest their efficacy in therapies in which additional anti-inflammatory and neuroprotective activities are beneficial for a patient.

Preclinical studies on additive and synergistic effects between pharmaceutical drugs and the natural products encourage randomized clinical trials of their combinations as the adjunct therapies [80]. Table 2 summarizes results from studies in animal models of pain, epilepsy, cancer, diabetes and mental disorders. It is important to emphasize that such preclinical animal studies are scarce and, in most cases, their limitations also include a lack of isobolic analysis. Synergistic effects of curcumin with another pleiotropic natural product, epigallocatechin gallate [81, 82], offer new multi-targeted combinations with anticancer drugs [83-85], in addition to their anti-inflammatory activities [24, 86]. From the perspective of combination therapies with curcumin, n-3 PUFA, or resveratrol, pleiotropic natural products were also shown to modulate serotonergic and dopaminergic systems in the brain, thus offering potential for add-on antidepressant or anxiolytic benefits (Table 3). Clinical trials supporting preclinical finding on potential antidepressant benefits are emerging [77, 87, 88]. Since depression is a common comorbidity in epilepsy, pain and other chronic diseases, these additional mood-stabilizing activities may support mental health management during pharmacotherapies. When comparing therapeutic indications between clinical (Table 1) and preclinical (Table 2) studies in combining drugs with natural products, only epilepsy and cancer currently show immediate translational promise. However, in addition to “canonical” challenges when developing new drugs via preclinical and clinical studies, additional challenges of incorporating natural products into prescribed medications are having a public domain status and medication non-adherence (adding “one more pill” may rather discourage a patient, despite clinical benefits).

**Medication Adherence as a New Challenge for Treating Chronic Diseases**

Approximately 50% of patients with chronic diseases struggle to take medications as prescribed [111], resulting in symptom exacerbation, and increased morbidity and mortality (Fig. 2). Adherence is defined by the World Health Organization as “the extent to which a person’s behavior - taking medication, following a diet, and/or executing lifestyle changes – corresponds with agreed recommendations from a health care provider”. Clinical consequences of non-adherence contribute to a decreased quality of life for patients and care givers. Financial consequences of decreased medication adherence include estimated $100-290 billion per year for the US health care insurance companies and patients [112], as well as revenue losses of $188 billion per year by the US pharmaceutical industry [113]. Global pharmaceutical industry have an estimated $564 billion loss per year due to patients’ non-adherence [113]. Therefore, improving medication adherence for chronic diseases is a win-win opportunity for patients and health care industry.

Medication adherence is a patient behavioral component of pharmacotherapy. Why does a patient struggle with long-term compliance with taking prescribed medication? For each patient, factors affecting adherence vary, and can be caused by comorbidities (anxiety, stress, depression, fatigue), financial burden, strict medication schedules, miscommunications with doctors, nurses or pharmacists, poor expectations and suboptimal education, or/and limited knowledge and involvement in managing symptoms [122, 123]. Persistence in taking medication can be challenged by drug-related adverse side effects, or by managing a large number of prescription medications [124-126]. Additional reasons are as trivial as forgetfulness and travel, and/or as serious as life style choices and ignorance. Patients with type 1 or 2 diabetes describe fear and embarrassment of injecting insulin as the leading cause of non-compliance [127]. Studies suggest that depression and adverse childhood experiences (ACEs) can be predictors of medication adherence [128-130]. Patient-related factors can be addressed by educating and empowering patients to develop persistence in self-management of pharmacotherapies and disease-related symptoms [3, 131].

**INCENTIVIZED THERAPIES**

**Psychobehavioral Incentives to Improve Medication Adherence**

Incentives have been explored as a strategy to improve patient’s motivation to comply with his/her pharmacotherapy. This strategy is illustrated in Fig. 3A. Rewarding a patient with incentives is a challenging task, since tangible external rewards can become counterproductive [132]. Financial incentives to reinforce medication adherence face such considerations as ethical, cost-effectiveness and sustainability [133-135]. Incentivizing diabetic patients was recently reviewed in the context of positive perception while
Table 1. Clinical studies showing clinical effects of combining pleiotropic natural products with pharmaceutical drugs.

| Indication                              | Drug                               | Natural Product       | Refs.  |
|-----------------------------------------|------------------------------------|-----------------------|--------|
| **ARTHRITIS**                           |                                    |                       |        |
| Osteoarthritis pain                     | NSAIDS                             | Curcumin              | [51]   |
| Knee osteoarthritis                     | NSAIDS, other analgesics           | Curcumin and Glucosamine | [52] |
| Knee osteoarthritis                     | NSAIDS                             | Curcumin              | [53]   |
| Knee osteoarthritis                     | NSAIDS, paracetamol                | n-3 PUFA              | [54]   |
| Rheumatoid arthritis                    | Diclofenac sodium                  | Curcumin              | [55]   |
| **PAIN**                                |                                    |                       |        |
| Burning mouth syndrome                  | Gabapentin                         | α-Lipoic acid         | [56]   |
| Postoperative pain                      | Opioid analgesics                  | Capsaicin             | [57]   |
| Chronic neck pain                       | Superoxide dismutase               | α-Lipoic acid         | [58]   |
| **EPILEPSY**                            |                                    |                       |        |
| Drug resistant epilepsy                 | Antiepileptic drugs                | n-3 PUFA              | [59]   |
| Drug resistant epilepsy                 | Antiepileptic drugs                | n-3 PUFA              | [60]   |
| Refractory seizures                     | Antiepileptic drugs                | n-3 PUFA              | [61]   |
| Intractable focal or generalized epilepsy| Antiepileptic drugs                | n-3 PUFA              | [62]   |
| **CANCER**                              |                                    |                       |        |
| Pancreatic cancer                       | Gemcitabine                        | Curcumin              | [63]   |
| Prostate cancer                         | Docetaxel                          | Curcumin              | [64]   |
| Leukemia                                | Imatinib                           | Curcumin              | [65]   |
| Breast cancer                           | Anthracycline-based drugs          | n-3 PUFA              | [66]   |
| Lung cancer                             | First-line chemotherapy            | n-3 PUFA              | [67]   |
| Breast cancer                           | Paclitaxel                         | n-3 PUFA              | [68]   |
| Prostate cancer                         | Lycopene                           | n-3 PUFA              | [69]   |
| Gastrointestinal                        |                                    | n-3 PUFA              | [70]   |
| **DIABETES**                            |                                    |                       |        |
| Type 2                                  | Insulin                            | Resveratrol           | [71]   |
| Type 2                                  | Insulin                            | Curcumin              | [72]   |
| Diabetes mellitus and hypertension      | Quinapril                          | α-Lipoic Acid         | NCT00795262 |
| Peripheral diabetic neuropathy          | Prostaglandin E1                   | α-Lipoic Acid         | [73]   |
| **MENTAL DISORDERS**                    |                                    |                       |        |
| Depression                              | Fluoxetine                         | Curcumin              | [40]   |
| Major depressive disorder               | Reserpine (rats)                   | Curcumin              | [74]   |
| Major depressive disorder               | Escitalopram                       | Curcumin              | [75]   |
| Major depressive disorder               | Selective serotonin reuptake inhibitors (SSRIs) | Curcumin              | [76]   |
| Depression                              | Psychotropic drugs                 | n-3 PUFA              | [77]   |
| Schizophrenia                           | Antipsychotic drugs                | Theanine              | [78, 79] |
Table 2. Preclinical studies showing effects of combining pleiotropic natural products with pharmaceutical drugs.

| Medical Condition | Drug            | Natural Product | Major Outcome                                                                 | Refs. |
|-------------------|-----------------|-----------------|--------------------------------------------------------------------------------|-------|
| Epilepsy          | Valproate       | Curcumin        | Curcumin enhanced antiseizure activity of subtherapeutic doses of valproate, provide anti-inflammatory and antioxidant effects. | [89]  |
|                   | Carbamazepine   | n-3 PUFA        | n-3 PUFA increased protection from seizures in combination with carbamazepine | [90]  |
| Depression        | Corticosterone  | Curcumin        | Curcumin and corticosterone reduces depressive-like behaviors, increased sucrose consumption and reduce mobility time | [91]  |
| Depression        | Fluoxetine, Mitrazapine | n-3 PUFA   | n-3 PUFA potentiated subtherapeutic doses of antidepressant drugs | [92, 93] |
| Pain              | Morphine        | Ginsenoids      | Ginsenoids and morphine yielded synergistic antinociception in nociceptive rats | [94]  |
| Pain              | Morphine        | n-3 PUFA        | n-3PUFA potentiated analgesia and prevented tolerance to morphine | [95]  |
| Cancer            | Capecitabine    | Curcumin        | Curcumin potentiated anticancer activity of capecitabine through the NF-κB pathway | [96]  |
| Cancer            | 5-Fluorouracil/ Oxaliplatin | Curcumin     | Gastric tumor volume was significantly reduced in mice when curcumin was added to a combination of 5-FU/oxiplatin combination. | [97]  |
| Cancer            | 5-Fluorouracil  | Resveratrol     | Resveratrol potentiated 5-FU anticancer activity in skin cancer mouse model | [98]  |
| Diabetic Neuropathy | Enalapril | α-Lipoic acid   | Enalapril with LA prevented vascular and neuronal damage in diabetic rats | [99]  |
| Ischemic Stroke   | Etanercept      | α-Lipoic acid   | Etanercept with LA enhanced recovery in cerebral infarct, motor deficit and stroke | [100] |
| Schizophrenia     | Clozapine       | α-Lipoic acid   | Clozapine with LA reversed schizophrenia-like symptoms in mice | [101] |

Table 3. Pleiotropic activities of selected natural products studied in humans. Studies and mechanism of enhancing positive mood and activating the brain reward system are also summarized.

| Natural Product | Preclinical Data on Antidepressant Activities and Interactions with the Reward System | Refs. |
|-----------------|--------------------------------------------------------------------------------------|-------|
| Curcumin        | Decreased serum corticosterone levels                                                | [14, 102-105] |
|                 | Increases serotonin by inhibition of monoamine oxidases                              |       |
|                 | Reduce immobility time and stress-induced neurodegeneration                           | [88, 91] |
| n-3 PUFA        | Stabilizes/increases levels of brain serotonin, affects serotonergic transmission     | [12]  |
| Resveratrol     | Increased serotonin levels in the brain                                              | [106] |
|                 | Inhibition of monoamine oxidases (MAO-A)                                             |       |
| L-acetylcarnitine | Enhances dopamine release                                                              | [107-109] |
|                 | Upregulation of mGlu2 Receptors                                                     |       |
| L-Theanine      | Increases dopamine levels in the brain                                               | [110] |
|                 | Increased levels of BDNF                                                            | [31]  |

decreasing intrinsic motivation by the patients [136, 137]. As alternatives to external incentives, motivational components of mobile and digital technologies for diabetes patients can address the sustainability challenges [138].

Integrating incentives into medical treatment is a new concept in which pharmacological and psychobehavioral elements are combined together into a network therapy (Figs. 3B and 3C). Such psychobehavioral element is a patient’s choice of using (or not using) a pleiotropic natural product and mHealth, thus becoming an empowerment tool for her/his engagement in the therapy. A choice is used as a tool to improve intrinsic motivation [139, 140]. Empowering patients through choices and shared decision-making has been studied [141-144], including epilepsy patients [145].
Clinical applications of patient empowerment using mHealth technologies were described for cancer, diabetes and other chronic medical indications [146-149]. Disease-specific serious games which incorporate choices and engagement show improved self-management behaviors in patients [150-152]. Integrating psychobehavioral incentives with pharmacotherapies can be presented in the context of network pharmacology (Figs. 1B, 3 and 4), a term usually reserved for describing multi-drug combination therapies and derived from system biology [33, 153]. Development and applications of multi-target, network pharmacology for the treatment of complex chronic diseases has been established for cancer [154, 155], neurotropic pain [156, 157], epilepsy [158], depression [159] and diabetes [160, 161]. Psychological contribution of the placebo effect to pharmacological outcomes has been extensively studied for several chronic medical conditions [162, 163]. Recently, adding psychobehavioral elements to the network pharmacology has been facilitated by disease-specific mobile medical apps [3]. Below, we describe specific examples of how mHealth technologies can further integrate pleiotropic natural products into molecular-behavioral combination therapies.

**Incentivized Therapy for Epilepsy**

Innovating medical treatments for epilepsy patients is driven by needs to address both the refractory epilepsy and significant medication non-adherence. Approximately 30% of epilepsy patients are refractory to antiseizure drugs despite taking more than one medication. Consequently this medical condition is subject to non-pharmacological treatments such as the ketogenic diet, vagus nerve stimulation, deep brain stimulation, or brain surgery [164]. Since only 48% of epilepsy patients become seizure-free after taking their first antiseizure drug [165-168], the incentivized therapies may offer better seizure control for newly diagnosed patients. (150,000-200,000 people in the US and approximately 2.4 million people worldwide are diagnosed with epilepsy each year, according to statistics presented by the World Health Organization and the Epilepsy Foundation). Additional challenge for effective treatments for epilepsy patients in prevalence of depression and anxiety as comorbidities [169]. To improve the therapies of pharmacoresistant epilepsy, medication non-adherence and comorbidities, the drug-device combination therapy consisting of antiseizure medications and a mobile medical app for epilepsy patients was proposed [3]. Herein we describe the incentivized therapy for epilepsy which comprises antiseizure pharmaceutical drugs, antiseizure natural products, and behavioral and self-management components delivered by the mHealth technology. We also review preclinical and clinical evidence for incorporating these elements into the network therapy.

**Table 1**: Medication adherence rates for selected chronic disorders and clinical consequences of non-adherence. Medication adherence values were obtained from medication-possession ratio (MPR) reported in retrospective studies [114-121]. For CVD, a meta-analysis value was used. Adherence data vary significantly in values depending on a population, type of study (prospective or retrospective) and methods used to measure adherence.
and status epilepticus. Data from clinical trials suggest that n-3 PUFA may be effective in reducing frequency of seizures in patients with refractory epilepsy [170]. DeGiorgio et al. showed in randomized controlled trial (RCT) that a 10-week treatment with fish oil daily dose of 1080 mg DHA/EPA was effective in reducing seizure frequency by 33% in refractory epilepsy adult patients taking 1-4 anticonvulsant drugs [60]. Previous studies with adult epilepsy patients taking fish oil for seizure control were inconclusive [62, 171, 172], however these studies were with higher doses, consistent with the recent finding from the DeGiorgio et al. study [60]. The importance of dosing n-3 PUFA in humans and animal studies was previously discussed [173]. In the recent study, pediatric patients with refractory epilepsy were subject to a 3-month treatment with daily fish oil containing 240 mg DHA and 360 mg EPA, resulting in over 50% of patients becoming seizure-free [59]. While these clinical trials were carried out with a small number of patients, the positive results are also supported by preclinical data in animal models of epilepsy [90, 174]. The mechanism by which n-3 PUFA exert their antiepileptic effects is not known although PUFA was shown to affect neuronal excitability in the hippocampus [175, 176] and also exhibit anti-neuroinflammatory properties [177]. The main PUFA component in the brain is DHA, and some models suggest that n-3 PUFA may modulate neuronal excitability via changing levels of sodium-potassium-chloride cotransporters NKCC1 and NKCC2 by affecting lipid rafts through brain cholesterol [178], and shifting conductance of potassium channels [179, 180]. Noteworthy, fatty acids were shown to suppress seizures [181, 182], at least in part due to binding to ionotropic glutamate AMPA receptors [183].

Curcumin and resveratrol exhibit antiseizure activities in animal models of epilepsy. Combinations of curcumin and subtherapeutic doses of antiepileptic drugs (valproate, phenytoin, phenobarbital and carbamazepine) showed increased protection against seizures in the MES and PTZ models of epilepsy [89]. In the PTZ-kindled mice model of epilepsy, curcumin was effective in a dose-dependent manner attenuating seizure severity and reducing depression-like behavior and memory impairment [184]. In the PTZ-treated rat model of chronic epilepsy, curcumin attenuated cognitive impairment, expression of proinflammatory cytokins in the hippocampus and glial activation [185]. Curcumin also exhibited antiepileptogenic activities in the kainate-induced temporal lobe epilepsy and post-status epilepticus in rats [186-188]. Similar effects were observed for resveratrol in the PTZ-kindled rats [189] and its anti-inflammatory activity via the AMPK/mTOR signaling pathway was found in the model of status epilepticus [190]. The use of resveratrol in epilepsy and status epilepticus has been discussed [191, 192]. Potential pharmacokinetic interactions between resveratrol and carbamazepine may prevent this particular combination to treat epileptic seizures [193], similarly to potential interactions between n-3 PUFA and carbamazepine [194].

The mHealth technologies specific for epilepsy patients comprise of mobile medical apps, online resources and wearables intended to help epilepsy self-management, including detecting and monitoring seizures [195-197]. Rapid progress in wireless and mobile EEG interfaces [198, 199] or the EDA-sensors offers unique opportunities for biofeedback-based streaming of digital content developed specifically for epilepsy patients [3]. Examples of online and mobile technologies and apps for epilepsy patients are studied and reviewed [195, 196, 200]. Design features of mobile medical apps intended to reduce frequency of epileptic seizures were previously described [3]. Pharmaceutical industry has been incorporating these new developments, including applications for epilepsy patients. For example, the UCB Pharma partnered with MC10 company in developing the Biostamp, a sensor for detecting seizure movements in epilepsy patients. Among many advances, wearable and mobile app technologies also include the SmartWatch (by Smart Monitor), Embrace (by Empatica), Seizalarm app (Seizalarm) or My Epilepsy (by the Epilepsy Foundation).

Behavioral therapy and self-management for epilepsy patients have been extensively studied and offer self-care strategies to reduce seizure frequency [201-206]. For example, significant reduction of seizures in epilepsy patients was observed during and after six months of psychological and self-management intervention [201]. A randomized trial of behavioral therapy showed a significant
reduction of seizure frequency in older adults with epilepsy [206]. Similar positive results were observed in randomized trial of behavioral interventions in patients with refractory epilepsy [205]. Behavioral-educational interventions were also effective in reducing seizures in children with epilepsy [202]. Clinical efficacy of Mozart’s music, including sonata K.448, in reducing seizures in patients with refractory epilepsy [207-209], supports listening to this music for 10 minutes daily as an additional self-care intervention [3]. Mobile medical apps are positioned to reduce and prevent seizures given feasibility and convenience for delivering and monitoring self-care and behavioral interventions. The gamification of mobile medical apps ensure engaging and rewarding content, making patients more eager to engage with their therapies, including medication adherence and disease-related, healthy habits. A recent review emphasizes further needs to study effectiveness of epilepsy self-management strategies [210].

Incentivized therapy for epilepsy incorporating antiseizure pharmaceutical drugs and natural products and self-care delivered by mHealth is illustrated in Fig. 4. The add-on administration of n-3 PUFA (1g or 0.6 g per day for adult or pediatric patients, respectively), when coupled with mobile medical app, may further improve control of seizures by engaging a patient with the therapy including additional antiseizure natural product and self-care behaviors. Epilepsy-specific behavioral therapy (including awareness of avoiding and managing stress and other seizure-precipitating triggers), educational elements, medication reminders and antiseizure music are provided to the patient via mHealth, hence delivering “behavioral” component of the resulting molecular-behavioral combination therapy. The psychobehavioral incentives of having a choice, feeling empowered, and shared-decision making regarding the add-on therapy targets patient intrinsic motivation (Fig. 3B and 3C), further supporting long-term compliance and persistence with the therapy. Epilepsy patients express their desires to be actively involved in choices and shared-decision making [145].

**Incorporation of Behavioral Interventions and Self-Care into the Incentivized Therapies for Chronic Diseases**

Chronic diseases such as neuropathic pain, epilepsy, cancer, diabetes, CVD, arthritis, asthma, or mental disorders are medical conditions that last at least a year, or are

![Fig. (4). Molecular-behavioral combination therapy for epilepsy patients. (A) Three components of the molecular-behavioral combination therapy are antiseizure pharmaceutical drug, n-3 PUFA as pharmacologically-active incentives, and mobile app delivering antiseizure music and epilepsy self-management content [3]. Given high prevalence of depression as comorbidity for chronic disorders, the add-on therapy (in shaded area) can be specifically prescribed for patients with refractory epilepsy and experiencing symptoms of depression. Mobile apps and software for treating depression and anxiety show promise in clinical trials [211-213]. In addition to n-3 PUFA, curcumin also can be developed as psychobehavioral incentives due to its antiseizure and antidepressant activities. (B) An example of a parallel study design to test the molecular-behavioral combination therapy in form of a drug-device combination product. Patients with refractory epilepsy are usually given two or more antiseizure drugs (Rx group). To establish efficacy of all possible combinations, such four-arm study can last 6-12 months, and can further include crossover, as was previously used to establish efficacy of n-3 PUFA in patients with refractory epilepsy [60], or/and a delayed start/prerandomization to reduce placebo responses [214]. Determining pharmacokinetic interactions between natural products and antiseizure drugs are important to ensure the safety of the drug-drug combination study (2nd and 4th arm), even though natural products may have prescription medicine status (e.g. n-3 PUFA as Lovaza®, or Vascepa®).]
permanent. Because of the long duration, chronic medical conditions challenge patients, caregivers and healthcare systems, and also pose a major economic burden [215, 216]. An additional challenge for managing a chronic disease happens after achieving remission and discontinuation of pharmacotherapies. The Center for Disease Control and Prevention (CDC) emphasized importance of behavioral components (such as physical activity, nutrition) which can prevent progression of chronic diseases [217]. Supporting healthy habits during the therapy and also after reaching remission (during the inactive-disease state) is critical for long-term improvements in therapy outcomes and health-related quality of life.

Patient self-care and disease self-management become important behavioral components of patient-centered health care [218, 219]. Self-care can be considered as a combination of disease self-management and self-efficacy, where self-management can be described as patient’s skills and behaviors affecting disease symptoms, and self-efficacy is patient’s motivation and perceived ability to engage in self-management behaviors. The relationship between self-management and self-efficacy is shown in Fig. 5A. Incorporation of disease-specific behavioral and self-care components into patient daily life has been facilitated using mHealth technologies. For example, listening to the antiseizure music and avoiding seizure-tractors are daily behavioral components to help epilepsy patients to reduce and prevent seizures. There is accumulating clinical evidence for other non-pharmacological, behavioral interventions for specific chronic medical conditions. Therapeutic physical exercise was validated for rheumatoid arthritis (RA) [220, 221], major depressive disorder [222], neurodegenerative disorders [223], neuropathic pain [224], diabetic cancer [225], or perioperative management, postoperative recovery and outcomes [226]. Physical exercise programs for patients with RA may additionally improve their health-related quality of life by improving sleep and fatigue [227]. Yoga improved disease-symptoms for patients with low-back pain [228-230], cancer-related fatigue [231, 232], osteoarthritis [233-235], epilepsy [236], asthma [237], diabetes [238] and PTSD [239]. Music-supported therapies include medical indications such as pain, epilepsy, stroke, myocardial infarct, dementia, depression, anxiety, and other psychiatric disorders (references in [3] and [240-242]). The pleiotropic nature of music is mediated by neurochemical changes in the brain, endocrinological and immune systems [243-245], activating the mesolimbic system and dopaminergic neurotransmission [246-251]. Recent studies suggest that exposure to Mozart and Bach music can upregulate brain-derived neurotropic factor (BDNF) [252, 253]. Nutrition-based interventions have shown clinical efficacy in reducing seizures in epilepsy patients [254-256], but more studies on pharmacokinetic interactions with antiepileptic drugs are needed [257, 258]. Nutrition has been effective non-pharmacological treatment for CVD [259], diabetes [260], or arthritis including combinations with physical exercise [261]. Taken together, cognitive behavioral therapy, music, nutrition, physical exercise and yoga are already being combined into behavioral interventions and self-care using mHealth [262-264].

Self-administration of an optional (add-on) treatment targets patient intrinsic motivation, and can promote long-lasting behavioral changes by engaging habit-forming mechanisms [265, 266]. As illustrated in Fig. 5B, an opportunity to self-administer the clinically-efficacious dose of the pleiotropic natural product and other self-care behaviors, leads to activating the reward system and creating a habit-forming loop. Engaging habit-forming neuronal networks in the brain may facilitate health-promoting behavioral benefits [267, 268]. mHealth and gamification principles offer additional tools to engage, monitor and virtually reward a patient [269-271]. While self-administration of pleiotropic natural products can improve pharmacotherapy outcomes, it is nonpharmacological treatments that hold long-term potential for introducing new healthy routines in chronically-ill patients. This aspect becomes critical once a chronically-ill patient reaches a stage of clinical remission and inactive disease state, since she/he is in a vulnerable state due to behavioral and lifestyle contribution to the disease and the therapy outcomes. Additional benefit of incorporating clinically-efficacious behavioral interventions is the opportunity to reduce dosing of pharmaceutical-based therapies (Fig. 5C). While this application is apparent for patients with neuropathic pain being treated with opioids, or arthritis patients taking NSAIDs and other anti-inflammatory medications, future clinical studies will evaluate its potential use in treating epilepsy, depression, cardiovascular and other chronic medical conditions [4, 5, 21, 25, 60, 191, 192].

Industry and Translational Considerations

This article describes the use of pleiotropic natural products in combinations with existing pharmaceutical drugs and self-care delivered by the mHealth technology. From the regulatory point of view, this is a multifaceted challenge, requiring judicious and cooperative endeavor to develop such integrated medical treatments. Incorporating natural product or self-care delivered by mHealth already creates numerous challenges, and integrating two or more modalities is even more difficult. Clinical development of drug-device combinations can be facilitated by a natural product having the status of prescribed medication, or mobile app reaching the status of regulated medical device.

For patients, many natural products are currently available as supplements, for which health claims and benefits are regulated by federal agencies [272]. Because dietary supplements market is becoming increasingly competitive due to fast growth, there are new tensions and opportunities to innovate these products. Converting natural products from dietary supplements into regulated medical treatments requires clinical studies on optimizing dosing, duration and drug-drug interactions to achieve maximum efficacy and safety for each specific medical indication. However, the lack of intellectual property protection of natural products is a challenge for developing them as medical treatments. A problem of patenting natural products was previously exemplified with curcumin [273, 274], whereas patenting guidelines also change for newly-discovered natural products [2]. Improving bioavailability of curcumin [275, 276], or generating derivatives of resveratrol [277, 278] are viable patenting strategies to improve their efficacy. To this end, combining natural products with disease-specific behavioral interventions via mHealth offers
The Power of Habit
self-administration of an incentive. The habit-forming loop scheme or those with depression to decrease dosing or number of medications. Trials will determine if this strategy also applies to epilepsy patients. NSAIDs and other anti-inflammatory drugs. Randomized clinical treatment of chronic, neuropathic pain with opioids, or arthritis with pharmaceutical drugs, an opportunity instantly applicable in the moment.

Integration of incentive-based nonpharmacological interventions means to deliver empowerment and disease self-management content and empowerment (perceived abilities to cope with, control and manage disease symptoms). Digital technologies become effective for chronic disease, improve the therapy outcomes and the health-related quality of life after reaching remission. Self-care consists of disease self-management (patient behaviors related to management and prevention of disease symptoms), self-efficacy and empowerment (perceived abilities to cope with, control and manage disease symptoms). Digital technologies become effective means to deliver empowerment and disease self-management content. Patients activate the habit-forming mechanism by a self-administration of an incentive. The habit-forming loop scheme is adapted from “The Power of Habit” by Charles Duhigg. Integration of incentive-based nonpharmacological interventions with pharmaceuticals can lead to decreasing the dose of pharmacological drugs, an opportunity instantly applicable in the treatment of chronic, neuropathic pain with opioids, or arthritis with NSAIDs and other anti-inflammatory drugs. Randomized clinical trials will determine if this strategy also applies to epilepsy patients or those with depression to decrease dosing or number of medications.

Given multiple components of the incentivized therapy, the discovery and characterization of synergistic effects among natural products, pharmaceutical drugs and mobile medical apps is challenging at both preclinical and clinical levels. At a preclinical level, it is important to test combinations of natural products and pharmaceutical drugs using obisodic analysis, or sub-effective therapeutic doses. At a clinical level, large-scale, controlled testing is challenging due to additional placebo-related responses, driven by spontaneous remissions, methodological bias and psychobiological mechanisms of positive expectations and learning. The neurobiological mechanisms of the placebo effect are mediated by specific neurotransmitters, including dopamine, neuropeptides and their receptors located in different brain structures. This end, the expectation-driven placebo effect may overlap with music and therapeutic games due to activating dopaminergic signaling in the patient’s reward system. One possible mechanism of such additional placebo-like effects is that music and judiciously-timed digital images can produce temporal expectations. To best of our knowledge, the synergistic effects between pharmacological and non-pharmacological treatments have not been demonstrated.

Optimal design of randomized and placebo-controlled clinical trials for any new therapy is critical for demonstrating its efficacy. Even for testing monotherapies, there are challenges to account for placebo effects and responses that are often disease-specific and interwoven with natural fluctuations of chronic disease symptoms. In the case of

Fig. (5). Roles of self-care and the reward system in the incentivized therapies. Due to the long duration of chronic medical conditions, healthy habits and self-care can slow down progression of the chronic disease, improve the therapy outcomes and the health-related quality of life after reaching remission. (A) Self-care consists of disease self-management (patient behaviors related to management and prevention of disease symptoms), self-efficacy and empowerment (perceived abilities to cope with, control and manage disease symptoms). Digital technologies become effective means to deliver empowerment and disease self-management content. Patients activate the habit-forming mechanism by a self-administration of an incentive. The habit-forming loop scheme is adapted from “The Power of Habit” by Charles Duhigg. (C) Integration of incentive-based nonpharmacological interventions with pharmaceuticals can lead to decreasing the dose of pharmacological drugs, an opportunity instantly applicable in the treatment of chronic, neuropathic pain with opioids, or arthritis with NSAIDs and other anti-inflammatory drugs. Randomized clinical trials will determine if this strategy also applies to epilepsy patients or those with depression to decrease dosing or number of medications.

an additional level of intellectual property protection by merging copyrights (lasting over 50 years) with a pharmacologically-active compound which exists in public domain. This strategy creates new regulatory challenges and requires closely working with the regulatory agencies to ensure the safety of patients and following proper regulatory mechanisms. Additional benefits of the regulatory pathway for developing natural products in combinations with mHealth include new strategies to innovate and validate new medical interventions, instead of following costly litigations (e.g. the 2015 Vascepa® case related to off-label claims).

Converting mobile apps into a regulated medical device requires pivotal clinical trials in support of regulatory clearance. Current regulatory guidelines indicate that apps delivering disease self-management content are likely exempt from premarket approval, subject to the discretion of the regulatory agencies. For combinations of mobile apps with natural products, their intended use for specific medical condition, marketing, and labelling must be supported by appropriate clinical studies, and subject to premarket notification or approval. A mobile app for tracking the use of dietary supplements, MyDS, was developed by the National Institute of Health Office for Dietary Supplements (the app was discontinued in June 2015). Regulatory challenges and growth of mHealth have resulted in excessive number of health-related and wellness apps, creating a problem of credibility and confusion. Thus also creating opportunities for digital technologies to be part of clinically-validated integrative medicine. The mHealth technology is becoming a part of personalized medicine, and several companies have been pioneering development of mobile medical apps and games as medical treatments. Health care providers support incorporation of mHealth into primary care practice and reimbursement policies.

Given multiple components of the incentivized therapy, the discovery and characterization of synergistic effects among natural products, pharmaceutical drugs and mobile medical apps is challenging at both preclinical and clinical levels. At a preclinical level, it is important to test combinations of natural products and pharmaceutical drugs using obisodic analysis, or sub-effective therapeutic doses. At a clinical level, large-scale, controlled testing is challenging due to additional placebo-related responses, driven by spontaneous remissions, methodological bias and psychobiological mechanisms of positive expectations and learning. The neurobiological mechanisms of the placebo effect are mediated by specific neurotransmitters, including dopamine, neuropeptides and their receptors located in different brain structures. To this end, the expectation-driven placebo effect may overlap with music and therapeutic games due to activating dopaminergic signaling in the patient’s reward system. One possible mechanism of such additional placebo-like effects is that music and judiciously-timed digital images can produce temporal expectations. To best of our knowledge, the synergistic effects between pharmacological and non-pharmacological treatments have not been demonstrated.

Optimal design of randomized and placebo-controlled clinical trials for any new therapy is critical for demonstrating its efficacy. Even for testing monotherapies, there are challenges to account for placebo effects and responses that are often disease-specific and interwoven with natural fluctuations of chronic disease symptoms. In the case of
epilepsy, the placebo effects and responses were observed for both antiseizure drugs and medical devices, and several study designs have been proposed to mitigate placebos [214], including adjusting “time to prerandomization” [292], or “delay start” [293]. Clinical testing of combinations of antiseizure drugs with natural products (n-3 PUFA) was accomplished using randomized and placebo-controlled crossover design with three periods in which patients with refractory epilepsy were receiving low- or high-dose of n-3 PUFA or placebo while taking their antiseizure medications [60]. Testing more complex combination therapies, such as those containing pharmaceutical drugs, natural products and mobile medical apps (e.g. shown in Fig. 4A) will require judicious design of parallel and randomized trials to account for placebo and nocebo effects, likely adding additional challenges associated with multiple testing sites. In addition to universal ethical aspects of reducing or enhancing the placebo effects in patients during the treatment of a chronic disease, additional ethical aspect of including the placebo arm in epilepsy patients is the increase of SUDEP (sudden unexplained death in epilepsy) [294].

From a translational perspective, the long-term premise of developing the combinations of pharmaceutical drugs, natural products and self-care is the creation of the molecular-behavioral combination therapies in which seamless integration of behavioral and pharmacological interventions is delivered. As illustrated in Fig. 4, the molecular-behavioral combination therapy for patients with epilepsy can consist of the antiseizure drug, n-3 PUFA and behavioral, self-management content (like listening to antiseizure music, avoiding seizure-triggers). Such strategy is also favorable for patients with neurological disorders in which inflammatory and behavioral components significantly contribute to disease symptoms. Large-scale, randomized and controlled clinical studies on interactions between behavioral and pharmacological interventions will shed more light on mutual relationships, yielding new rational strategies for personalized, precision and preventive medicine [295-297]. Translational perspectives for developing broad-spectrum approach and integrative therapies are discussed for mental disorders [298, 299] and cancer [80]. Better understanding of interactions between natural products and drug targets, and mechanisms by which enriched environment (nutrition, physical exercise), cell metabolism and epigenetics may affect pharmacological properties of drug candidates [300, 301], will facilitate design of incentivized therapies combining the most effective components.

CONCLUSION

Pleiotropic natural products or nonpharmacological treatments can be incorporated into pharmacotherapies as psychobehavioral incentives to improve therapy outcomes for chronically-ill patients. Such integrative approach results in molecular-behavioral combination therapies, possible to deliver by digital medical technologies. There is an apparent need for controlled clinical trials to account for the placebo responses and to validate the effectiveness of these pharmacological and non-pharmacological combinations. Incentivized medical treatments offer an opportunity to improve medication adherence and clinical efficacy of existing pharmaceutical drugs. In addition, the ability to catalyze habit-changing healthy behaviors in patients favors improvements in the health-related quality of life during pharmacotherapy and after reaching remission. This aspect offers unique opportunities to bridge symptomatic treatments with preventive medicine, and has implications for public health by addressing risk factors and burden of chronic diseases [302, 303]. Lastly, once the drug-device combination product is approved by a regulatory agency, merging copyrights of mHealth software with natural products will afford new proprietary products containing natural products currently existing in public domain. Engaging patients with their therapies using mHealth-delivered behavioral interventions will improve their experience with medical treatment. Taken together, combining the clinical efficacy of natural products and pharmaceutical-based treatments with self-care will advance patient-centered health care.

ABBREVIATIONS

BDNF = brain-derived neurotropic factor  
CVD = cardiovascular disease  
DHA = docosahexanoic acid  
EDA = electrodermal activity  
EEG = electroencephalograph  
EPA = eicosapentaenoic acid  
5-FU = 5-fluorouracil  
LA = α-lipoic acid  
MES = maximum electroshock  
mHealth = mobile health technologies  
MPR = medication possession ratio  
NSAIDs = nonsteroidal anti-inflammatory drugs  
PPARs = peroxisome proliferator-activated receptors  
PTZ = pentylenetetrazol  
n-3 PUFA = omega-3 polyunsaturated fatty acids  
RCT = randomized controlled trial

CONFLICT OF INTEREST

GB is a cofounder of Epicadence PBC, Public Benefit Corporation, a company developing mobile software as medical devices for treating chronic medical conditions.

ACKNOWLEDGEMENTS

GB acknowledges past support from the National Institute of Health Grant U01 NS 066991 during this work.

REFERENCES

[1] Grady PA, Gough LL. Self-management: a comprehensive approach to management of chronic conditions. Am J Public Health 2014; 104(8): e25-31.  
[2] Harrison C. Patenting natural products just got harder. Nat Biotechnol 2014; 32(5): 403-4.  
[3] Bulaj G. Combining non-pharmacological treatments with pharmacotherapies for neurological disorders: a unique interface of the brain, drug-device, and intellectual property. Front Neurol 2014; 5: 126.
[4] Yates CM, Calder PC, Ed Rainger G. Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. Pharmacol Ther 2014; 141(3): 272-82.

[5] Oliveira AS, Sousa E, Vasconcelos MH, Pinto M. Curcumin: A Natural Lead for Potential New Drug Candidates. Curr Med Chem 2015; 22(36): 4196-232.

[6] Moura FA, de Andrade KQ, dos Santos JC, Goulart MO. Lipidic Acid: its antioxidant and anti-inflammatory role and clinical applications. Curr Top Med Chem 2015; 15(5): 458-83.

[7] Park S, Karunarathne U, Jeong NH, Jeon JH, Lee IK. Physiological effect and therapeutic application of alpha lipic acid. Curr Med Chem 2014; 21(32): 3636-45.

[8] Park EJ, Pezzuto JM. The pharmacology of resveratrol in animals and humans. Biochim Biophys Acta 2015; 1852(6): 1071-113.

[9] Tome-Carneiro J, Larroza M, Gonzalez-Sarrias A, Tomas-Barberan FA, Garcia-Conesa MT, Espin JC. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des 2013; 19(34): 6064-93.

[10] Shirani A, Okuda DT, Stuve O. Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis. Neurotherapeutics 2016; 13(1): 58-69.

[11] Tizabi Y, Hurley LL, Qualls Z, Akinfiresoye L. Relevance of the crossroad from diseases and depression. Molecules 2014; 19(12): 20864-79.

[12] Freeman MP, Hibbeln JR, Wisner KL. Efficacy and safety of omega-3 fatty acids. Subcell Biochem 2008; 49: 133-43.

[13] McNulty DN, Bonilla DL, Chapkin RS. n-3 Fatty acids uniquely affect the cytokine profile in multiple sclerosis patients: a double-blind, placebo-controlled, randomized clinical trial. Neuroimmunomodulation 2014; 21(6): 291-6.

[14] Nathan PJ, Lu K, Gray M, Oliver C. The neuropharmacology of L-S-phenylalanine(N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent. J Herb Pharmacother 2006; 6(2): 21-30.

[15] Lyon MR, Kapoor MP, Junea LR. The effects of L-theanine (Suntheanine(R)) on objective sleep quality in boys with attention deficit hyperactivity disorder (ADHD): a randomized, double-blind, placebo-controlled clinical trial. Altern Med Rev 2011; 16(4): 348-54.

[16] Luthra PM, Lal N. Potential modes of action of curcumin: a review of its anti-inflammatory, anti-oxidant, immune-modulating and neuroprotective effects. Sci Pharm 2015; 2: 38.

[17] Lopresti AL, Hood SD, Drummond PD. Multiple antidepressant and neuroprotective effects of alpha lipoic acid. Curr Med Chem 2014; 21(32): 3636-45.

[18] Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid improves subclinical left ventricular dysfunction in asymptomatic patients with type 1 diabetes. Rev Diabet Stud 2013; 10(1): 56-67.

[19] Hegazy SK, Tolba OA, Mostafa TM, Eid MA, El-Afify DR. Alpha-lipoic acid improves subclinical left ventricular dysfunction in asymptomatic patients with type 1 diabetes. Rev Diabet Stud 2013; 10(1): 56-67.

[20] Hager K, Kenkles M, McAfoose J, Engel J, Munch G. Alpha-lipoic acid as a new treatment option for Alzheimer's disease—a 48 months follow-up analysis. J Neural Transm Suppl 2007; (72): 189-93.

[21] Kaku H. Neurobiological effects of the green tea constituent L-theanine on cognitive function, cognition, and neuroprotective effects. J Psychopharmacol 2011; 25(1): 58-67.

[22] Hegazy SK, Tolba OA, Mostafa TM, Eid MA, El-Afify DR. Alpha-lipoic acid improves subclinical left ventricular dysfunction in asymptomatic patients with type 1 diabetes. Rev Diabet Stud 2013; 10(1): 56-67.

[23] Kaku H. Neurobiological effects of the green tea constituent L-theanine on cognitive function, cognition, and neuroprotective effects. J Psychopharmacol 2011; 25(1): 58-67.

[24] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[25] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[26] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[27] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[28] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[29] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[30] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[31] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[32] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[33] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[34] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[35] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[36] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[37] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[38] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[39] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[40] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[41] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[42] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[43] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[44] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[45] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[46] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[47] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[48] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[49] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[50] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.

[51] Kulkarni SS, Canto C. The molecular targets of resveratrol. Intensive Care Med 2006; 32(12): 1954-67.
extended administration in osteoarthritis patients. Altern Med Rev 2010; 15(4): 337-44.

[52] Belcaro G, Dugall M, Luzzi R, et al. Meriva(R)+Glucosamine versus Condroitin+Glucosamine in patients with knee osteoarthritis: an observational study. Eur Rev Med Pharmacol Sci 2014; 18(24): 3959-63.

[53] Nakagawa Y, Maki S, Yamada S, et al. Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study. J Orthop Sci 2014; 19(6): 933-9.

[54] Hill CL, March LM, Atikten D, et al. Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose. Ann Rheum Dis 2016; 75(1): 23-9.

[55] Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res 2012; 26(11): 1719-25.

[56] Lopez-D’Alessandro E, Escovich L. Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: a randomized, double-blind, placebo controlled trial. Med Oral Patol Oral Cir Bucal 2011; 16(5): e635-40.

[57] Hartrick CT, Pestano C, Carlson N, Hartrick S. Capsaicin instillation for postoperative pain following total knee arthroplasty: a preliminary report of a randomized, double-blind, parallel-group, placebo-controlled, multicentre trial. Clin Drug Invest 2011; 31(12): 977-82.

[58] Leitzman Mauro G, Cataldo P, Barbera G, Sanfilippo A. alpha-Lipoic acid and superoxide dismutase in the management of chronic neck pain: a prospective randomized study. Drugs R&D 2014; 14(1): 1-7.

[59] Reda DM, Abd-El-Fatah NK, Omar Tel S, Darwinf OA. Fish Oil Intake and Seizure Control in Children with Medically Resistant Epilepsy. N Am J Med Sci 2015; 7(7): 317-21.

[60] DeGiorgio CM, Miller PR, Harper R, et al. Fish oil (n-3 fatty acids) in drug resistant epilepsy: a randomised placebo-controlled crossover study. J Neurol Neurosurg Psychiatry 2015; 86(1): 65-70.

[61] DeGiorgio CM, Miller P, Meymandi S, Gornbein JA. Omega-3 fatty acids (fish oil) for epilepsy, cardiac risk factors, and risk of SUDEP: Clues from a pilot, double-blind, exploratory study. Epilepsy Behav 2008; 13(4): 681-4.

[62] Bromfield E, Dworetzky B, Hurwitz S, et al. A randomized trial of polysaturated fatty acids for refractory epilepsy. Epilepsy Behav 2008; 12(1): 187-90.

[63] Kanai M, Yoshimura K, Asada M, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 2011; 68(1): 157-64.

[64] Mahammedi H, Blanchet E, Pouget M, et al. The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study. Oncology 2016; 90(2): 69-78.

[65] Ghalaut VS, Sangwan L, Dahiya K, Ghalaut PS, Dhankhar R, et al. Omega-3 fatty acids via dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients. Clin Neuropharmacol 2011; 34(4): 155-60.

[66] Reeta KH, Mehla J, Pahuja M, Gupta YK. Pharmacokinetic and pharmacodynamic interactions of valproate, phenytoin, and phenobarbitone with curcumin in experimental models of epilepsy in rats. Pharmacoepidemiol Drug Saf 2016; 25(4): 399-407.

[67] Brusnoy P, Molnar GA, Mohas M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011; 106(3): 383-9.

[68] Wickenberg J, Ingemansson SL, Hlebowicz J. Effects of Curcuma longa (turmeric) on postprandial plasma glucose and insulin in healthy subjects. Nutr J 2010; 9: 43.

[69] Brusnoy P, Molnar GA, Hlebowicz J, et al. Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study. J Orthop Sci 2014; 19(6): 933-9.

[70] Hill CL, March LM, Atikten D, et al. Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose. Ann Rheum Dis 2016; 75(1): 23-9.

[71] Lyoo IK, Yoon S, Kim TS, et al. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am J Psychiatry 2012; 169(9): 937-45.

[72] Krishnan JC, Chanda S, Choudhury D, et al. Omega-3 fatty acids and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: a randomized, double-blind, placebo controlled trial. Med Oral Patol Oral Cir Bucal 2011; 16(5): e635-40.

[73] Lane K, Levitt G, Hristov N, et al. Omega-3 fatty acids and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: a randomized, double-blind, placebo controlled trial. Med Oral Patol Oral Cir Bucal 2011; 16(5): e635-40.

[74] Lyoo IK, Yoon S, Kim TS, et al. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am J Psychiatry 2012; 169(9): 937-45.

[75] Miodownik C, Maayan R, Ratner Y, et al. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients. Clin Neuropharmacol 2011; 34(4): 155-60.

[76] Ritsner MS, Miodownik C, Ratner Y, et al. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J Clin Psychiatry 2011; 72(1): 34-42.

[77] Block KI, Gyllenhaal C, Lowe L, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol 2015; 35 Suppl: S276-304.

[78] Eom DW, Lee JH, Kim YJ, et al. Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells. BMJ Rep 2015; 4(8): 461-6.

[79] Chung SS, Vadgama JV. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFkappaB signaling. Anticancer Res 2015; 35(1): 39-46.

[80] Miodownik C, Maayan R, Ratner Y, et al. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients. Clin Neuropharmacol 2011; 34(4): 155-60.

[81] Ritsner MS, Miodownik C, Ratner Y, et al. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J Clin Psychiatry 2011; 72(1): 34-42.

[82] Samadi AK, Bilssland A, Georgakilas AG, et al. A multi-targeted approach to suppress tumor-promoting inflammation. Semin Cancer Biol 2015; 35 Suppl: S151-84.

[83] Wang Z, Dabrosin C, Yin X, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol 2015; 35 Suppl: S224-43.

[84] Anderson G, Maes M. Oxidative/nitrosative stress and immunoinflammatory pathways in depression: treatment implications. Curr Pharm Des 2014; 20(23): 3812-47.

[85] Su KP, Lai HC, Yang HT, et al. Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. Biol Psychiatry 2014; 76(7): 559-66.

[86] Sammukhani J, Anuvadaya A, Tripathi CB. Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: an acute and chronic study. Acta Pol Pharm 2011; 68(5): 769-75.

[87] Reeta KH, Mehla J, Pahuja M, Gupta YK. Pharmacokinetic and pharmodynamic interactions of valproate, phenytoin, and phenobarbitone and curcumin with curcumin in experimental models of epilepsy in rats. Pharmacoepidemiol Drug Saf 2011; 20(3): 399-407.

[88] Pages N, Maurois P, Delplanque B, Bae P, Vamecq J. Brain anticonvulsant protection of mice given chronic curcumin in models of status epilepticus. Eur J Pharmacol 2013; 700(3): 303-10.
under various fatty acid and magnesium diet conditions. Prostaglandins Leukot Essent Fatty Acids 2012; 87(2-3): 63-70.

[91] Huang Z, Zhong XM, Li ZY, Feng CR, Pan AJ, Mao QQ. Curcumin reverses corticosterone-induced depressive-like behavior and decrease in brain BNDF levels in rats. Neurosci Lett 2011; 493(3): 145-8.

[92] Laino CH, Fonseca S, Sterin-Speziale N, Slobodianik N, Reines A. Potentiation of omega-3 fatty acid antidepressant-like effects with low non-antidepressant doses of fluoxetine and mirtazapine. Eur J Pharmacol 2010; 648(1-3): 117-26.

[93] Laino CH, Garcia P, Podesta MF, Hocht C, Slobodianik N, Reines A. Fluoxetine potentiation of omega-3 fatty acid antidepressant effect: evaluating pharmacokinetic and brain fatty acid-related aspects in rodents. J Pharm Sci 2014; 103(10): 3316-25.

[94] Yoon MH, Kim KS, Lee HG, et al. Synergistic interaction between intrathecal ginsenosides and morphine on formalin-induced nociception in rats. J Pain 2011; 12(7): 774-81.

[95] Escudero GE, Romanuk CB, Toledo ME, Olivera ME, Manzo RH, Laino CH. Analgesia enhancement and prevention of tolerance to morphine: beneficial effects of combined therapy with omega-3 fatty acids. J Pharm Pharmacol 2015; 67(9): 1251-62.

[96] Kunnunakkara AB, DiDianjane P, Anand P, et al. Curcumin sensitizes human colorectal cancer to capcitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 2009; 125(9): 2187-97.

[97] Zhou X, Wang W, Li P, et al. Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrogene and nitrotoxic mechanisms. Schizop Res 2016; 185(2-3): 163-70.

[98] Li Y-C, Wang F-M, Pan Y, et al. Antidepressant-like effects of curcuma on serotonin receptor-coupled AC-cAMP pathway in chronic unpredictable mild stress of rats. J Neurochem Pharmacol 2015; 765: 258-67.

[99] Wu MH, Huang CC, Hocht C, et al. Effect of L-Acetylcarnitine on serotonergic receptor-coupled AC-cAMP pathway in human colorectal cancer cells: anti-cancer activity. J Pharm Pharmacol 2015; 67(9): 1251-62.

[100] Davis KL, Tangirala M, Meyers JL, Wei W. Real-world outcomes of US type 2 diabetes patients initiating analog basal insulin therapy. Curr Med Res Opin 2013; 29(9): 1083-91.

[101] Sabaté E. Adherence to long-term therapies: evidence for action. Switzerland: World Health Organization, 2003.

[102] Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353(5): 487-97.

[103] Thomas F, Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a challenge for tailored interventions. Patient Prefer Adher 2013; 7: 675-82.

[104] Davis L, Brunetti L, Lee EK, Yoon N, Cho SH, Suh DC. Effects of computerized physician order entry on medication turnaround time and orders requiring pharmacist intervention. Res Social Adm Pharm 2014; 10(5): 756-67.

[105] Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmaco 2013; 4: 91.

[106] Davis L, Brunetti L, Lee EK, Yoon N, Cho SH, Suh DC. Effects of computerized physician order entry on medication turnaround time and orders requiring pharmacist intervention. Res Social Adm Pharm 2014; 10(5): 756-67.

[107] Hergen JG, Timmers L, Elders PJ, Vervloet M, van Dijk L. Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions. Patient Prefer Adher 2013; 7: 675-82.

[108] Mclauglin T, Hogue SL, Stang PE. Once-daily buPROPion associated with improved patient adherence compared with twice-daily buPROPion in depression treatment. Am J Ther 2007; 14(2): 221-5.

[109] Chowdhury R, Khan H, Heyden E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34(38): 2948-55.

[110] Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther 2005; 27(7): 1064-73.

[111] Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmaco 2013; 4: 91.

[112] Davis L, Brunetti L, Lee EK, Yoon N, Cho SH, Suh DC. Effects of computerized physician order entry on medication turnover time and orders requiring pharmacist intervention. Res Social Adm Pharm 2014; 10(5): 756-67.

[113] Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc 2011; 86(4): 304-14.

[114] Davis L, Brunetti L, Lee EK, Yoon N, Cho SH, Suh DC. Effects of computerized physician order entry on medication turnover time and orders requiring pharmacist intervention. Res Social Adm Pharm 2014; 10(5): 756-67.

[115] Medic G, Higashi K, Littlewood KJ, Diez T, Granstrom O, Kahn RS. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatr Dis Treat 2013; 9: 119-31.
[332] Dcci EL, Koestner R, Ryan RM. A meta-analytic review of experiments examining the effects of extrinsic rewards on intrinsic motivation. Psychol Bull 1999; 125(6): 627-68; discussion 92-700.

[333] Szmukler G. Ethical problems with paying patients to improve adherence to treatment. BMJ 2013; 347: f6837.

[334] DeFulio A, Silverman K. The use of incentives to reinforce medication adherence. Prev Med 2012; 55 Suppl: S86-94.

[335] Sen AP, Sewell TB, Riley EB, et al. Financial incentives for home-based health monitoring: a randomized controlled trial. J Gen Intern Med 2014; 29(5): 770-7.

[336] Blondon K, Klasna P, Coleman K, Pratt W. An exploration of attitudes toward the use of patient incentives to support diabetes self-management. Psychol Health 2014; 29(5): 552-63.

[337] Petry NM, Cengiz E, Wagner JA, Hood KK, Carria L, Tamborlane WV. Incentivizing behaviour change to improve diabetes care. Diabetes Obes Metab 2013; 15(12): 1071-6.

[338] Arons E, Froisland DH, Skovsseth SO, et al. Mobile health applications to assist patients with diabetes; lessons learned and design implications. J Diabetes Sci Technol 2012; 6(5): 1197-206.

[339] Cameron J, Banko KM, Pierce WD. Pervasive negative effects of rewards on intrinsic motivation: The myth continues. Behav Anal 2001; 24(1): 1-44.

[340] Patall EA, Cooper H, Robinson JC. The effects of choice on intrinsic motivation and related outcomes: a meta-analysis of research findings. Psychol Bull 2008; 134(2): 270-300.

[341] Hain DJ, Sandy D. Partners in care: patient empowerment through shared decision-making. Nephrol Nurs J 2013; 40(2): 153-7.

[342] Baars JE, Markus T, Kuipers EJ, van der Woude CJ. Patients' preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study. Digestion 2010; 81(2): 113-9.

[343] Clayman ML, Bylund CL, Chewning B, Makoul G. The Impact of Patient Participation in Health Decisions Within Medical Encounters: A Systematic Review. Med Decis Making 2016; 36(4): 427-52.

[344] Nota I, Drossaert CH, Taal E, Vonkeman HE, van de Laar MA. The Impact of Patient Participation in Decisions About Disease modifying anti-rheumatic drugs: a cross-sectional survey. BMC Musculoskelet Disord 2014; 15: 333.

[345] Govender M, Bowen RC, German ML, Bulaj G, Bruggers CS. Mobile health technology-enabled person-centered care for the “big five” chronic conditions: scoping review. J Med Internet Res 2015; 17(3): e77.

[346] Tejada S, Martorell M, Capo X, Tur JA, Pons A, Sureda A. N-3 polyunsaturated fatty acids in the management of Epilepsy. Curr Top Med Chem 2013; 15(1): 3-14.

[347] Kim W, McMurray DN, Chapkin RS. n-3 polyunsaturated fatty acids--physiological relevance of dose. Prostaglandins Leukot Essent Fatty Acids 2010; 82(4-6): 155-8.

[348] Yeung AH, Bulaj et al. Omega-3 Fatty Acids in the Management of Epilepsy. Curr Top Med Chem 2016; 16(17): 1897-905.

[349] Kim W, McMurray DN, Chapkin RS. n-3 polysaturated fatty acids--physiological relevance of dose. Prostaglandins Leukot Essent Fatty Acids 2010; 82(4-6): 155-8.

[350] Yeung AH, Bulaj et al. Omega-3 fatty acid supplementation in patients with chronic epilepsy: a randomized trial. Epilepsy Behav 2005; 7(2): 253-8.

[351] Kim W, McMurray DN, Chapkin RS. n-3 polysaturated fatty acids--physiological relevance of dose. Prostaglandins Leukot Essent Fatty Acids 2010; 82(4-6): 155-8.

[352] Trepaparz H, Kwong K, Domenichello AF, Chen CT, Bazinet RP, Burnham WM. Intravenous infusion of docosahexaenoic acid increases serum concentrations in a dose-dependent manner and increases seizure latency in the maximal PTZ model. Epilepsy Behav 2015; 49: 1-9.

[353] Xu XP, Erichsen D, Borjeson SI, Dahlin M, Amark P, Elinder F. Polysaturated fatty acids and cerebrospinal fluid from on the ketogenic diet open a voltage-gated K channel: a putative mechanism of antiseizure action. Epilepsy Res 2008; 80(1): 57-66.
Molecular-Behavioral Combination Therapies

[180] Yazdi S, Stein M, Elinder F, Andersson M, Lindahl E. The Molecular Basis of Polyunsaturated Fatty Acid Interactions with the Shaker Voltage-Gated Potassium Channel. PLoS Comput Biol 2016; 12(1): e1004704.

[181] Chang P, Terbach N, Plant N, Chen PE, Walker MC, Williams RS. Seizure control by ketogenic diet-associated medium chain fatty acids. Neuropharmacology 2013; 69: 105-14.

[182] Wlaz P, Socala K, Nieoczym D, et al. Acute anticonvulsant effects of capric acid in seizure tests in mice. Prog Neuropsychopharmacol Biol Psychiatry 2015; 57: 110-6.

[183] Chang P, Augustin K, Boddum K, et al. Seizure control by decanoic acid through direct AMPA receptor inhibition. Brain Res 2016; 139(Pt 2): 431-43.

[184] Chowdhary KM, Mishra A, Porokov VV, Goel RK. Ameliorative effect of Curcumin on seizure severity, depression like behavior, learning and memory deficit in post-pentylenetetrazole-kindled mice. Eur J Pharm 2013; 704(1-3): 33-40.

[185] Kaur H, Patro I, Tikoo K, Sandhir R. Curcumin attenuates inflammatory response and cognitive deficits in experimental model of chronic epilepsy. Neurochem Int 2015; 89: 40-50.

[186] Jiang Z, Guo M, Shi C, et al. Protection against cognitive impairment and modification of epileptogenesis with curcumin in a post-status epilepticus model of temporal lobe epilepsy. Neuroscience 2015; 310: 362-71.

[187] Kiasalari Z, Roghani M, Khalili M, Rahmati B, Balusehjojoorjarad T. Antiepileptic effect of curcumin on kainate-induced model of temporal lobe epilepsy. Pharm Biol 2013; 51(12): 1572-8.

[188] Mishra V, Shuai B, Kodali M, et al. Resveratrol Treatment after Status Epilepticus Restrains Neurodegeneration and Abnormal Neurogenesis with Suppression of Oxidative Stress and Inflammation. Sci Rep 2015; 5: 17807.

[189] Saha L, Chakrabarti A. Understanding the anti-kindling role and its mechanism of Resveratrol in Pentylenetetrazole induced-kindling in a rat model. Pharmacol Biochem Behav 2014; 120: 57-64.

[190] Wang SJ, Bo QY, Zhao XH, Yang X, Chi ZF, Liu XW. Resveratrol pre-treatment reduces early inflammatory responses induced by status epilepticus via miR-122 signaling. Brain Res 2013; 1492: 122-9.

[191] Pallas M, Ontino-Sahagun D, Benito-Andres P, Ponce-Regalado MD, Rojas-Mayorquin AE. Resveratrol in epilepsy: preventive or treatment opportunities? Front Biosci (Landmark Ed) 2014; 19: 1057-64.

[192] Shetty AK. Promise of resveratrol for easing status epilepticus and epilepsy. Pharmacol Ther 2011; 131(3): 209-86.

[193] Bedada SK, Neerati P. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers. Phytother Res 2015; 29(5): 701-6.

[194] Yuen AW, Sander JW, Flugel D, et al. Erthyrocyte and plasma fatty acid profiles in patients with epilepsy: does carbamazepine affect omega-3 fatty acid concentrations? Epilepsie Behav 2008; 12(2): 317-23.

[195] Shergog R, Bamps YA, Patel A, et al. Managing Epilepsy Well: Emerging e-Tools for epilepsy self-management. Epilepsy Behav 2013; 29(1): 133-40.

[196] Panderer PS, Bhullar KK. Smartphone applications for seizure management. Health Informatics J 2014; 22(2): 209-20.

[197] Jory C, Shankar R, Coker D, McLean B, Hanna J, Newman C. Safe and sound? A systematic literature review of seizure detection methods for personal use. Seizure 2016; 36: 4-15.

[198] Tseng KC, Lin BS, Wong AM, Lin BS. Design of a mobile phone computer interface-based smart multimedia controller. Sensors (Basel) 2015; 15(3): 5518-30.

[199] Ramirez R, Palencia-Lefler M, Giraldo S, Vamvakousis Z. Musical neurofeedback for treating depression in elderly people. Front Neurosci 2015; 9: 354.

[200] Liu X, Wang R, Zhou D, Hong Z. Feasibility and acceptability of smartphone applications for seizure self-management in China: Questionnaire study among people with epilepsy. Epilepsy Behav 2015; 55: 57-61.

[201] Gillham RA. Refractory epilepsy: an evaluation of psychological methods in outpatient management. Epilepsia 1990; 31(4): 427-32.

[202] Tieffenberg JA, Wood EL, Alonso A, Tossuttii MS, Vicente MF. A randomized field trial of ACINDES: a child-centered training model for children with chronic illnesses (asthma and epilepsy). J Urban Health 2000; 77(2): 280-97.

[203] May TW, Pfafflin M. The efficacy of an educational treatment program for patients with epilepsy (MOSES): results of a controlled, randomized study. Modular Service Package Epilepsy. Epilepsia 2002; 43(5): 539-49.

[204] Lundgren T, Dahl J, Melin L, Kies B. Evaluation of acceptance and commitment therapy for drug refractory epilepsy: a randomized controlled trial. South Africa J Behav Med 2006; 47(12): 2173-9.

[205] Lundgren T, Dahl J, Yardi N, Melin L. Acceptance and Commitment Therapy and yoga for drug-refractory epilepsy: a randomized controlled trial. Epilepsy Behav 2008; 13(1): 102-8.

[206] McLaughlin DP, McFarland K. A randomized trial of a group based cognitive behavior therapy program for older adults with epilepsy: the impact on seizure frequency, depression and psychosocial well-being. J Behav Med 2011; 34(3): 201-7.

[207] Coppola G, Toro A, Operto F, et al. Mozart's music in children with drug-refractory epileptic encephalopathies. Epilepsy Behav 2015; 50: 18-22.

[208] Lin LC, Lee WT, Wang CH, et al. Mozart K.448 acts as a potential add-on therapy in children with refractory epilepsy. Epilepsy Behav 2011; 20(3): 490-3.

[209] Dastghieb SS, Layegh P, Sadeghi R, Foroughipour M, Shoebi A, Gorji A. The effects of Mozart's music on interictal activity in epileptic patients: systematic review and meta-analysis of the literature. Curr Neurol Neurosci Rep 2014; 14(1): 420.

[210] Fleeman N, Bradley PM, Lindsay B. Care delivery and self management strategies for children with epilepsy. Cochrane Database Syst Rev 2015: 12: CD006245.

[211] Roepke AM, Jaffee SR, Riffle OM, McGonigal J, Broome R, Maxwell B. Randomized Controlled Trial of SuperBetter, a Smartphone-Based/Internet-Based Self-Help Tool to Reduce Depressive Symptoms. Games Health J 2015; 4(3): 235-46.

[212] Ebert DD, Zarski AC, Christensen H, et al. Internet and computer-based cognitive behavioral therapy for anxiety and depression in youth: a meta-analysis of randomized controlled outcome trials. PLoS One 2015; 10(3): e0119895.

[213] Briney AJ, Gunn R, Russell JK, Ary DV. MoodHacker Mobile Web App With Email for Adults to Self-Manage Mild-to-Moderate Depression: Randomized Controlled Trial. JMIR Mhealth Uhealth 2016; 4(1): e8.

[214] Goldenholz DM, Goldenholz SR. Response to placebo in clinical epilepsy trials-Old ideas and new insights. Epilepsie Res 2016; 122: 15-25.

[215] Ross D, Armen B with Anita C, Anusuya C, In Kyu K, Soojung K, Kevin K. An Unhealthy America: The Economic Burden of Chronic Disease -- Charting a New Course to Save Lives and Increase Productivity and Economic Growth. 2007.

[216] Goodman RA, Posner SF, Huang ES, Parekh AK, Koh HK. Neurtransmitters and mood disorders: the state of the evidence for physical activity interventions for adults with rheumatoid arthritis: 2007 to present. Int J Clin Rheumtol 2012; 7(5): 489-503.

[217] CDC report. The Power of Prevention. Chronic disease... the public health challenge of the 21st century. 2009. 1-16. Web site. http://www.cdc.gov/chronicdisease/pdf/2009-power-of-prevention.pdf.

[218] Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. JAMA 2002; 288(19): 2469-75.

[219] Brenk-Franz K, Strauss B, Tiesler F, et al. The Influence of Adult Attachment on Patient Self-Management in Primary Care - The Need for a Personalized Approach and Patient-Centred Care. PLoS One 2015; 10(9): e0136723.

[220] Iversen MD, Brawerman M, Iversen CN. Recommendations and the state of the evidence for physical activity interventions for adults with rheumatoid arthritis: 2007 to present. Int J Clin Rheumatol 2012; 7(5): 489-503.

[221] O'Grady M, Fletcher J, Ortiz S. Therapeutic and physical fitness exercise prescription for older adults with joint disease: an exercise prescription for older adults with rheumatoid arthritis: 2007 to present. Int J Clin Rheumatol 2012; 7(5): 489-503.

[222] Mura G, Moro MF, Patten SB, Carta MG. Exercise as an add-on strategy for the treatment of major depressive disorder: a systematic review. CNS Spectr 2014; 19(6): 496-508.
144 Current Clinical Pharmacology, 2016, Vol. 11, No. 2

[223] Tomlinson CL, Patel S, Meek C, et al. Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev 2012; (7): CD002817.

[224] Dobson JL, McMillan J, Li L. Benefits of exercise intervention in reducing neuropathic pain. Front Cell Neurosci 2014; 8: 102.

[225] Baumann FT, Bloch W, Beulertz J. Clinical exercise interventions in pediatric oncology: a systematic review. Pediatr Res 2013; 74(4): 366-74.

[226] Hoogeboom TJ, Dronkers JJ, Hulzebos EH, van Meeteren NL. Baumann FT, Bloch W, Beulertz J. Clinical exercise interventions in pediatric oncology: a systematic review. Pediatr Res 2013; 74(4): 366-74.

[227] Durcan L, Wilson F, Cunnane G. The effect of exercise on sleep and fatigue in rheumatoid arthritis: a randomized controlled study. J Rheumatol 2014; 41(10): 1966-73.

[228] Cramer H, Lauche R, Haller H, Dobos G. A systematic review and meta-analysis of yoga for low back pain. Clin J Pain 2013; 29(5): 450-60.

[229] Cramer H, Lauche R, Hohmann C, Langhorst J, Dobos G. Yoga for chronic neck pain: a 12-month follow-up. Pain Med 2013; 14(4): 541-8.

[230] Cramer H, Lauche R, Hohmann C, et al. Randomized-controlled trial comparing yoga and home-based exercise for chronic neck pain. Clin J Pain 2013; 29(3): 216-23.

[231] Kiecolt-Glaser JK, Bennett JM, Andridge R, et al. Yoga's impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial. J Clin Oncol 2014; 32(10): 1040-9.

[232] Taso CJ, Lin HS, Lin WL, Chen SM, Huang WT, Chen SW. The effect of yoga exercise on improving depression, anxiety, and fatigue in women with breast cancer: a randomized controlled trial. J Nurs Res 2014; 22(3): 155-64.

[233] Ebnezar J, Nagarathna R, Yogitha B, Nagendra HR. Effects of an integrated approach of hatha yoga therapy on functional disability, pain, and flexibility in osteoarthritis of the knee joint: a randomized controlled study. J Altern Complement Med 2012; 18(5): 463-72.

[234] Ebnezar J, Nagarathna R, Yogitha B, Nagendra HR. Effect of integrated yoga therapy on pain, morning stiffness and anxiety in osteoarthritis of the knee joint: A randomized control. Int J Yoga 2012; 5(1): 28-36.

[235] Cheung C, Wyman JF, Resnick B, Savik K. Yoga for managing chronic neck pain: a 12-month follow-up. Pain Med 2013; 14(4): 541-8.

[236] Van der Kolk BA, Stone L, West J, et al. Yoga as an adjunctive treatment for posttraumatic stress disorder: a randomized controlled trial. J Clin Psychiatry 2014; 75(6): e559-65.

[237] Najafi Ghezeljeh T, Mohades Ardebili F, Rafii F, Haghihi H. The Effects of Music Intervention on Background Pain and Anxiety in Burn Patients: Randomized Controlled Clinical Trial. J Burn Care Res 2015 [Epub ahead of print].

[238] Shirani Bidabadi S, Mehryar A. Music therapy as an adjunct to standard treatment for obsessive compulsive disorder and comorbid anxiety and depression: A randomized clinical trial. J Affect Disord 2015; 184: 13-7.

[239] Gruhlik LC, Patricio MC, Moreira DM. Mozart, but not the Beatles, reduces systolic blood pressure in patients with myocardial infarction. Acta Cardiol 2015; 70(6): 703-6.

[240] Koelsch S. Brain correlates of music-evoked emotions. Nat Rev Neurosci 2014; 15(3): 170-80.

[241] Chanda ML, Levitin DJ. The neurochemistry of music. Trends Cogn Sci 2013; 17(4): 179-93.

[242] Fancourt D, Ockelford A, Belai A. The psychoneuroimmunological effects of music: A systematic review and a new model. Brain Behav Immun 2014; 36: 15-26.

[243] Cramer H, Lauche R, Haller H, Dobos G. A systematic review and meta-analysis of yoga for low back pain. Clin J Pain 2013; 29(5): 450-60.

[244] Xing Y, Chen W, Wang Y, et al. Music exposure improves spatial cognition by enhancing the BDNF level of dorsal hippocampal subregions in the developing rats. Brain Res Bull 2016; 121: 131-7.

[245] Xing Y, Xia Y, Kendrick K, et al. Mozart, Mozart Rhythm and Retrograde Mozart Effects: Evidence from Behaviours and Neurobiology. Biosci Rep 2016; 6: 18744.

[246] Baumann FT, Bloch W, Beulertz J. Clinical exercise interventions in pediatric oncology: a systematic review. Pediatr Res 2013; 74(4): 366-74.

[247] Gold BP, Frank MJ, Bogert B, Brattico E. Pleasurable music affects reinforcement learning according to the listener. Front Psychol 2013; 4: 541.

[248] Salimpoor VN, Benovoy M, Larcher K, Dagher A, Zatorre RJ. Anatomically distinct dopamine release during anticipation and experience of peak emotion to music. Nat Neurosci 2013; 14(2): 257-62.

[249] Salimpoor VN, van den Bosch J, Kovacevic N, McIntosh AR, Dagher A, Zatorre RJ. Interactions between the nucleus accumbens and auditory cortices predict music reward value. Science 2013; 340(6129): 216-9.

[250] Katsyri J, Hari R, Ravaja N, Nummenmaa L. Just watching the game ain't enough: striatal fMRI reward responses to successes and failures in a video game during active and vicarious watching. Front Hum Neurosci 2013; 7: 278.

[251] Cole SW, Yao DJ, Knutson B. Reactivity and reward-related neural activation during a serious videogame. PloS One 2012; 7(3): e33909.

[252] Fancourt D, Ockelford A, Belai A. The psychoneuroimmunological effects of music: A systematic review and a new model. Brain Behav Immun 2014; 36: 15-26.

[253] McIlroy J, McMillan J, Li L. Benefits of exercise intervention in reducing neuropathic pain. Front Cell Neurosci 2014; 8: 102.

[254] Baumann FT, Bloch W, Beulertz J. Clinical exercise interventions in pediatric oncology: a systematic review. Pediatr Res 2013; 74(4): 366-74.

[255] Messier SP, Mihalko SL, Legault C, et al. Mediterranean diets versus a low-fat diet on glycaemic control in individuals with type 2 diabetes. Eur J Clin Nutr 2014; 68(7): 767-72.

[256] Klein P, Tyrilikova I, Mathews GC. Dietary treatment in adults with refractory epilepsy: a review. Neurology 2014; 83(11): 1978-85.

[257] Kvennefeld M, Selmer KK, Nakken KO, Iversen PO, Taubøll E. A prospective study of the modified Atkins diet for adults with idiopathic generalized epilepsy. Epilepsia Behav 2015; 53: 197-201.

[258] Kvennefeld M, Taubøll E, Selmer KK, Iversen PO, Nakken KO. Modified Atkins diet may reduce serum concentrations of antiepileptic drugs. Acta Neurol Scand 2015; 131(3): 187-90.

[259] Widmer RJ, Flammer AJ, Lerman LO, Lerman A. The Mediterranean diet, its components, and cardiovascular disease. Am J Med 2015; 128(3): 229-38.

[260] Lasa A, Miranda J, Bullo M, et al. Comparative effect of two Mediterranean diets versus a low-fat diet on glycemic control in individuals with type 2 diabetes. Eur J Clin Nutr 2014; 68(7): 767-72.

[261] Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA 2013; 310(12): 1263-70.

[262] Beltran A, Li R, Ater J, et al. Adapting a Videogame to the Needs of Pediatric Cancer Patients and Survivors. Games Health J 2013; 2(4): 213-21.

[263] Duncan M, Vandelanotte C, Kolt GS, et al. Effectiveness of a web-and mobile phone-based intervention to promote physical activity and healthy eating in middle-aged males: randomized controlled trial of the ManUp study. J Med Internet Res 2014; 16(6): e136.

[264] Du H, Venkatakrishnan A, Youngblood GM, Ram A, Pirollo P. A Group-Based Mobile Application to Increase Adherence in Exercise and Nutrition Programs: A Factorial Design Feasibility Study. JMIR Mhealth Uhealth 2016; 4(1): e4.

[265] Institute of Medicine (US) Committee on Health and Behavior: Research, Practice, and Policy. Health and Behavior: The Interplay of Biological, Behavioral, and Societal Influences. Washington (DC): National Academies Press (US); 2001. 5. Individuals and Families: Models and Interventions. Available from: http://www.ncbi.nlm.nih.gov/books/NBK43749/ [Internet].

[266] Maizes V, Rakel D, Niemiec C. Integrative medicine and patient-centered care. Explore 2009; 5(5): 277-89.

[267] Gold BP, Frank MJ, Bogert B, Brattico E. Pleasurable music effects reinforcement learning according to the listener. Front Psychol 2013; 4: 541.

[268] Gold BP, Frank MJ, Bogert B, Brattico E. Pleasurable music affects reinforcement learning according to the listener. Front Psychol 2013; 4: 541.
Molecular-Behavioral Combination Therapies

Current Clinical Pharmacology, 2016, Vol. 11, No. 2 145

[269] Cole SW, Yoo DJ, Knutson B. Interactivity and reward-related neural activation during a serious videogame. PLoS One 2012; 7(3): e33909.

[270] Kato PM, Cole SW, Bradlyn AS, Pollock BH. A video game improves behavioral outcomes in adolescents and young adults with cancer: a randomized trial. Pediatrics 2008; 122(2): e305-17.

[271] Baranowski T, Buday R, Thompson D, Lyons EJ, Lu AS, Baranowski J. Developing Games for Health Behavior Change: Getting Started. Games Health J 2013; 2(4): 183-90.

[272] Finley JW, Finley JW, Ellwood K, Hoadley J. Launching a new food product or dietary supplement in the United States: industrial, regulatory, and nutritional considerations. Annu Rev Nutr 2014; 34: 421-47.

[273] Jayaraman KS. US patent office withdraws patent on Indian herb. Nature 1997; 389(6646): 6.

[274] Marshall E, Bagla P. India applauds U.S. patent reversal. Science 1997; 277(5331): 1429.

[275] Shakeri A, Sahebkar A. Optimized curcumin formulations for the treatment of Alzheimer's disease: A patent evaluation. J Neurosci Res 2016; 94(2): 111-3.

[276] Bandyopadhyay D. Farmer to pharmacist: curcumin as an anti-invasive and antinmetastatic agent for the treatment of cancer. Front Chem 2014; 2: 113.

[277] Pezzuto JM, Kondratyuk TP, Ogas T. Resveratrol derivatives: a patent review. J Nat Prod 1997; 60(1): 1-7.

[278] Villalba JM, de Cabo R, Alcain FJ. A patent review of sirtuin activators: an update. Expert Opin Ther Pat 2013; 23(12): 1529-46.

[279] Shuren J. The FDA's role in the development of medical mobile health technologies. N Engl J Med 2014; 371(4): 372-9.

[280] Cortez NG, Cohen IG, Kesselheim AS. FDA regulation of mobile health technologies. N Engl J Med 2014; 371(4): 372-9.

[281] Engel JS, Thomas PR, Bailey RL, Thurn AL. MyDS: A Mobile Application to Track Dietary Supplements Use. FASEB J 2011; 25(1): Supplement 341.7.

[282] Kuehn BM. Is there an app to solve app overload? JAMA 2015; 313(14): 1405-7.

[283] Steinuhiel SR, Muse ED, Topol EJ. The emerging field of mobile health. Sci Transl Med 2015; 7(283): 283rv3.

[284] Hayes DF, Markus HS, Leslie RD, Topol EJ. Personalized medicine: risk prediction, targeted therapies and mobile health technology. BMC Med 2014; 12: 37.

[285] Daniel H, Sulmasy LS, Health and Public Policy Committee of the American College of Physicians. Policy Recommendations to Guide the Use of Telemedicine in Primary Care Settings: An American College of Physicians Position Paper. Ann Intern Med 2015; 163(10): 787-9.

[286] Benedetti F, Carlino E, Pedeimonte A. Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects. Lancet Neurol 2016; 15(7): 736-47.

[287] van Diepen RM, Cohen MX, Denys D, Mazaheri A. Attention and temporal expectations modulate power, not phase, of ongoing alpha oscillations. J Cogn Neurosci 2015; 27(8): 1573-86.

[288] Lappe C, Trainor LJ, Herholz SC, Pantev C. Cortical plasticity induced by short-term multimodal musical rhythm training. PLoS One 2011; 6(6): e21493.

[289] Nozadaran S. Exploring how musical rhythm entrains brain activity with electroencephalogram frequency-tagging. Philos Trans R Soc Lond B Biol Sci 2014; 369(1658): 20130393.

[290] Bailes F, Dean RT, Pearce MT. Music cognition as mental time travel. Sci Rep 2013; 3: 2690.

[291] Enck P, Bingle U, Schiedewolwski M, Rief W. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov 2013; 12(3): 191-204.

[292] French JA, Gil-Nagel A, Malerba S, Kramer L, Kumar D, Bagiella E. Time to prereandomization monthly seizure count in perampanel trials: A novel endpoint study. Neurology 2015; 84(20): 2014-20.

[293] Goldenholz DM, Moss R, Scott J, Auh S, Theodore WH. Confusing placebo effect with natural history in epilepsy: A big data approach. Ann Neurol 2015; 78(3): 329-36.

[294] Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol 2011; 10(11): 961-8.

[295] Epi PMC. A roadmap for precision medicine in the epilpsies. Lancet Neurol 2015; 14(12): 1219-28.

[296] Walker LE, Mirza N, Yip VL, Marson AG, Pirmohamed M. Personalized medicine approaches in epilepsy. J Intern Med 2015; 277(2): 218-34.

[297] Gerlag DM, Norris JM, Tak PP. RA: from risk factors and pathogenesis to prevention: Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment. Rheumatology (Oxford) 2016; 55(4): 607-14.

[298] Schumann G, Binder EB, Holte A, et al. Stratified medicine for mental disorders. Eur Neuropsychopharmacol 2014; 24(1): 5-50.

[299] Wittchen HU, Knappe S, Andersson G, et al. The need for a behavioural science focus in research on mental health and mental disorders. Int J Methods Psychiatr Res 2013; 22 Suppl 1: S1-22.

[300] Landgrave-Gomez J, Mercado-Gomez O, Guervara-Guzman R. Epigenetic mechanisms in neurological and neurodegenerative diseases. Front Cell Neurosci 2015; 9: 58.

[301] Neuffer PD, Bamman MM, Muoio DM, et al. Understanding the Cellular and Molecular Mechanisms of Physical Activity-Induced Health Benefits. Cell Metab 2015; 22(1): 4-11.

[302] Bauer UE, Briss PA, Goodman RA, Bowman BA. Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA. Lancet 2014; 384(9937): 45-52.

[303] Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859): 2242-60.